Lenvima Approved for Common Thyroid Cancer

February 13, 2015 4:38 PM

2 0

FRIDAY, Feb. 13, 2015 (HealthDay News) -- Lenvima (lenvatinib) has been approved by the U.S. Food and Drug Administration to treat differentiated thyroid cancer (DTC) that has progressed despite radioactive iodine therapy, the agency said Friday in a news release.

DTC is the most common type of thyroid cancer, the FDA said. Nearly 63,000 Americans were diagnosed with thyroid cancer in 2014 and about 1,890 died from it, according to the U.S. National Cancer Institute. The thyroid gland is in the neck and helps regulate the body's metabolism.

Read more

To category page